Next 10 |
2024-03-27 16:50:31 ET Gainers: Athira Pharma ( ATHA ) +5% . ContextLogic ( WISH ) +5% . Angi ( ANGI ) +4% . Xeris Biopharma Holdings ( XERS ) +4% . Inozyme Pharma ( INZY ) +3% . Losers: MillerKnoll ( ...
Data adds to increasing body of evidence supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and dementia with Lewy bodies Results from explorator...
2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
2024-02-22 17:07:23 ET More on Athira Pharma Seeking Alpha’s Quant Rating on Athira Pharma Historical earnings data for Athira Pharma Financial information for Athira Pharma Read the full article on Seeking Alpha For further details see: At...
Enrollment completed in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease; topline data expected in second half of 2024 On track to initiate first-in-human studies of ATH-1105 for the treatment of amyotrophic latera...
RENO, NV / ACCESSWIRE / February 15, 2024 / Athena Gold Corporation (OTCQB:AHNR)(CSE:ATHA) (" Athena " or the " Company ") is pleased to announce it has successfully completed an Induced Polarization/Resistivity (the " Survey ") at its 100% owned Crow Springs Project (" Project ") located approx...
BOTHELL, Wash., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced publication of research highlighting the neuroprot...
2024-01-11 09:59:58 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Covid-vaccine makers top laggard list, LLY and WST top gainers list For further detail...
Completed enrollment in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease and expects topline data in second half of 2024 Plans to initiate first-in-human studies of ATH-1105 to treat amyotrophic lateral sclerosis i...
Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial continuation and potential clinically meaningful activity of fosgonimeton Potential first-in-class approach focused on HGF modulation for treatme...
News, Short Squeeze, Breakout and More Instantly...
Athira Pharma Inc. Company Name:
ATHA Stock Symbol:
NASDAQ Market:
Data adds to increasing body of evidence supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neu...
Data adds to increasing body of evidence supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and dementia with Lewy bodies Results from explorator...
Enrollment completed in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease; t...